N/A N=545 Patterns of Care and Outcomes in Patients With Metastatic Bone Tumors (METABONE)
Metastatic Bone Tumor
Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=57 The Effect of Glitazone Treatment on Bone Marrow and Bone Marrow Cells
Change in Bone Mineral Density · Change in Bone Marrow Fat Content
Primary: Difference in Percent Change in Bone Mineral Density (BMD) From Baseline to 14 Weeks Between the Rosiglitazone Group and the Placebo Group — -1.3; 0.3 Percent change…
Phase 3 N=75 Effects of Anorexia Nervosa on Peak Bone Mass
Anorexia Nervosa
Primary: Change in Bone Density Over a 12-month Period — 0.045; 0.280 score on a scale — p=.109
N/A N=90 Exploration of Blood Flow Regulation to Bone in Humans
Bone Blood Flow Regulation
Primary: Tibial Blood Perfusion — 0.54; -1.47; 0.43; 2.08 μM (concentration)
Phase 1 N=19 Melatonin Osteoporosis Prevention Study
Osteoporosis · Osteopenia
Primary: The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Serum Osteocalcin (OC) Levels in Women After 6 Months, as Compared to Baseline — -0.6; 1.83 ng/mL
Phase 2 N=22 Bone Material Comparison in Maxillary Sinus Augmentation
Alveolar Bone Resorption · Sequela · Tooth Extrusion
Primary: Bone Density - Limited View CBCT (Cone-beam Computed Tomography) Measurements — 14.4; 1.5 percentage of bone height shrinkage
Phase 2 N=28 Effects of rhIGF-1 on Bone Metabolism in Adolescent Girls With Anorexia Nervosa
Disorder of Bone Density and Structure, Unspecified
Primary: Change in Spine Bone Density (g/cm^2) — -0.00558 gm/cm^2 — p=0.40
Phase 2 N=42 Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients.
Renal Transplant Osteodystrophy
Primary: Bone Mineral Density of Spine at 6 Months — 0.98; 0.97 gm/cm^2
Phase 2 N=33 A Study of the Specificity and Sensitivity of 5- Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors
Brain Neoplasms
Primary: Establish a Safe Dose for Oral 5-ALA Administration — 0; 0; 0; 0 Dose Limiting Toxicity
Phase 2 N=40 Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors
Malignant Brain Tumors
Primary: Number of Participants With Objective Response — 2; 2; 4; 19 Participants
N/A N=866 Dissemination of a Theory-Based Bone Health Program in Online
Osteoporosis · Health Behaviors
Primary: Changes in Osteoporosis Knowledge, Self-efficacy/Outcome Expectations for Calcium Intake and Exercise, Health Behaviors (Calcium Intake, Exercise) — 19.8; 19.3; 16.7…
N/A N=141 Renal Osteodystrophy: An Individual Management Approach
Kidney Failure, Chronic
Primary: Change in Quantitative Computed Tomography (QCT) Bone Mineral Density of the Hip — -10.71; 5.72; -3.52; .2 g/cm^3 — p=.443
Phase 3 N=78 Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients
Hematological Malignancies
Primary: Percentage Change in Bone Mineral Density From Baseline to 6 and 12 Months — 0.06; -2.61; -3.63; -4.85 Percentage change
N/A N=62 Immunohistochemical Evaluation of Protein P16 Expression in Ovarian Germ Cell Tumors.
Ovarian Neoplasms · Germ Cell Tumors · Immunohistochemistry
Primary: P16 Evaluation in Ovarian Germ Cell Tumors — 7; 4; 0; 6 units on a scale — p=0.001
N/A N=9 A Histomorphometric Analysis Following Sinus Augmentation Using Two Different Bone Graft Materials.
Missing Teeth
Primary: Percentage of New Vital Bone. — 16.33; 26.11; 30.5; 39.67 percentage of new vital bone